Join Growin Stock Community!

Kala bio, inc.KALA.US Overview

US StockHealthcare
(No presentation for KALA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KALA AI Insights

KALA Overall Performance

KALA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KALA Recent Performance

1.26%

Kala bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

KALA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KALA Key Information

KALA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KALA Profile

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Price of KALA

KALA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KALA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.16
PB Ratio
8.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.16
PB Ratio
8.34
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is KALA's latest earnings report released?

    The most recent financial report for Kala bio, inc. (KALA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KALA's short-term business performance and financial health. For the latest updates on KALA's earnings releases, visit this page regularly.

  • How much debt does KALA have?

    As of the end of the reporting period, Kala bio, inc. (KALA) had total debt of 29.94M, with a debt ratio of 1.2. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KALA have?

    At the end of the period, Kala bio, inc. (KALA) held Total Cash and Cash Equivalents of 21.1M, accounting for 0.84 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KALA's EPS continuing to grow?

    According to the past four quarterly reports, Kala bio, inc. (KALA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KALA?

    Kala bio, inc. (KALA)'s Free Cash Flow (FCF) for the period is -10.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 125.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of KALA?

    The latest valuation data shows Kala bio, inc. (KALA) has a Price-To-Earnings (PE) ratio of -0.15 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.